Cisplatin‐Resistant Lung Adenocarcinoma Cells Exhibit Increased Proangiogenic Capacity in a Microphysiological Model of Tumor Neovascularization
Cancer Medicine · 2026
DOI: 10.1002/cam4.72267 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Elisabet A Olsen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Bioinnovation Program, Tulane University, New Orleans, Louisiana, USA. Hauptthemen laut MEDLINE: Cisplatin, Drug Resistance, Neoplasm, Neovascularization, Pathologic, Adenocarcinoma of Lung. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Congressionally Directed Medical Research Programs.
Abstract (Originalsprache)
Carcinomas commonly recur and progress rapidly after a period of remission following platinum‐based therapy. This clinical scenario suggests that surviving drug‐resistant tumor cells are dormant or slow‐cycling before re‐entering a rapid growth phase. Remodeling of the recurrent tumor microenvironment (TME) contributes to high rates of metastasis, but little is known about differences in TME remodeling before therapy and after recurrence. This study explores selection for cisplatin‐resistant subpopulations of A549 lung adenocarcinoma cells in culture to derive populations for modeling features of the recurrent TME. A cisplatin dose of 25 μM killed approximately 80% of the cells while sparing enough cells to allow re‐expansion of sufficient cell numbers for downstream experimentation. Expanded cisplatin‐resistant derivatives (Cis‐R A549) exhibited features of mesenchymal transition (EMT) such as cellular hypertrophy, loss of cell–cell contacts, and upregulation of alpha‐smooth muscle actin mRNA. In 3D culture, Cis‐R A549 spheroids were loosely aggregated and dysmorphic in comparison to the compact and spherical parent A549 spheroids. The Ki67 index of Cis‐R A549 in 2D and 3D spheroid culture was markedly lower than that of parent A549, suggesting a state of pseudo‐dormancy with slow cycling. Cis‐R A549 upregulated multiple genes associated with the evolution of a more aggressive TME and displayed significantly increased proangiogenic capacity in a microphysiological model of tumor angiogenesis. This study establishes a methodological framework for engineering the recurrent TME with drug‐resistant cancer cell line derivatives selected via high‐dose exposure in culture. Increased angiogenesis induced by Cis‐R A549 suggests that anti‐angiogenic therapy may be more beneficial in the setting of recurrent disease following first‐line therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bioinnovation Program, Tulane University, New Orleans, Louisiana, USA.
- Department of Biomedical Engineering, Tulane University School of Science & Engineering, New Orleans, Louisiana, USA.
- Tulane Cancer Center, Louisiana Cancer Research Center, New Orleans, Louisiana, USA.
- Department of Physiology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
ORCID-Profile: Omar M K Ahmad, Mark J Mondrinos
Förderung
- Congressionally Directed Medical Research Programs
Zitieren
APA
Olsen, E. A., Kpeli, G. W., Ahmad, O. M. K., Uribe, I., & Mondrinos, M. J. (2026). Cisplatin‐Resistant Lung Adenocarcinoma Cells Exhibit Increased Proangiogenic Capacity in a Microphysiological Model of Tumor Neovascularization. Cancer Medicine. https://doi.org/10.1002/cam4.72267
Vancouver
Olsen EA, Kpeli GW, Ahmad OMK, Uribe I, Mondrinos MJ. Cisplatin‐Resistant Lung Adenocarcinoma Cells Exhibit Increased Proangiogenic Capacity in a Microphysiological Model of Tumor Neovascularization. Cancer Medicine. 2026. doi:10.1002/cam4.72267
BibTeX
@article{Olsen2026,
author = {Olsen, Elisabet A and Kpeli, G Wills and Ahmad, Omar M K and Uribe, Isabel and Mondrinos, Mark J},
title = {Cisplatin‐Resistant Lung Adenocarcinoma Cells Exhibit Increased Proangiogenic Capacity in a Microphysiological Model of Tumor Neovascularization},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72267}
}
EUVIMED